Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAD52 | P43351 | 2/20 | 0.39 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.39 |
| ▸ | CDK4 | P11802 | 1/20 | 0.39 |
| ▸ | CCND1 | P24385 | 1/20 | 0.39 |
| ▸ | MTOR | P42345 | 1/20 | 0.38 |
| ▸ | ADK | P55263 | 1/20 | 0.38 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.37 |
| ▸ | HPGD | P15428 | 3/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | MAOA | P21397 | 2/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.37 |
| ▸ | GLA | P06280 | 2/20 | 0.37 |
| ▸ | CASP1 | P29466 | 2/20 | 0.37 |
| ▸ | CASP7 | P55210 | 2/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4509432 | 0.80 | DYRK1A (0.40) | RAD52SMARCA2ALDH1A1KDM4EHPGD | |
| SCHEMBL4503223 | 0.79 | MAPK10 (0.50) | RAD52SMARCA2MTORADKNISCH | |
| SCHEMBL4503458 | 0.78 | CDK4 (0.43) | RAD52SMARCA2CDK4CCND1ALDH1A1 | |
| SCHEMBL3817086 | 0.77 | MTOR (0.33) | MTORADKNISCHALDH1A1KDM4E | |
| SCHEMBL313794 | 0.75 | — | — | |
| SCHEMBL3389993 | 0.74 | CYP3A4 (0.48) | ALDH1A1KDM4EHSD17B10SMN1; SMN2ADRA2A | |
| SCHEMBL8058607 | 0.69 | DYRK1A (0.49) | RAD52SMARCA2CDK4CCND1ALDH1A1 | |
| SCHEMBL4504196 | 0.69 | CDK4 (0.41) | RAD52CDK4CCND1ALDH1A1KDM4E | |
| SCHEMBL4507544 | 0.69 | RAD52 (0.48) | RAD52SMARCA2MTORADKNISCH | |
| SCHEMBL7055250 | 0.69 | RAD52 (0.48) | RAD52SMARCA2MTORADKNISCH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8252814-B2 | Agents and crystals for improving excretory potency of urinary bladder | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-08-28 | — | — | US | disclosed |
| US-20090264467-A1 | Agents and crystals for improving excretory potency of urinary bladder | ISHIHARA YUJI | 2009-10-22 | — | — | US | disclosed |
| US-7462628-B2 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-09 | — | — | US | disclosed |
| EP-1891954-A2 | Acetylcholinesterase inhibitors for improving excretory potency of urinary bladder | Takeda Pharmaceutical Company Limited (JP) | 2008-02-27 | — | — | EP | disclosed |
| US-20070232538-A1 | Uses of polypeptides | TAKEDA PHARMACEUTICAL COMPANY, LTD (JP) | 2007-10-04 | — | — | US | disclosed |
| US-20070021391-A1 | Preventive/remedy for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-01-25 | — | — | US | disclosed |
| US-20060281725-A1 | Agents and crystals for improving excretory potency of urinary bladder | ISIHARA YUJI | 2006-12-14 | — | — | US | disclosed |
| US-7138533-B2 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-11-21 | — | — | US | disclosed |
| US-7132547-B2 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-11-07 | — | — | US | disclosed |
| US-20060211675-A1 | Preventives/remedies for urinary disturbance | ISHIHARA YUJI | 2006-09-21 | — | — | US | disclosed |
| EP-1310490-A1 | GPR14 ANTAGONIST | Takeda Chemical Industries, Ltd. (JP) | 2003-05-14 | — | — | EP | disclosed |
| EP-1308513-A1 | USE OF POLYPEPTIDE | Takeda Chemical Industries, Ltd. (JP) | 2003-05-07 | — | — | EP | disclosed |
| US-6534496-B1 | Prophylactic and/or therapeutic drug for obesity and obesity associated diseasestor diabetes with a reduced risk for central side effects and high universality in usage. Another object of the a lipolytic agent, or a prophylactic and/or | TAKEDA CHEMICAL INDUSTRIES, INC. (JP) | 2003-03-18 | — | — | US | disclosed |
| US-20020177593-A1 | Agents and crystals for improving excretory potency of urinary bladder | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2002-11-28 | — | — | US | disclosed |
| EP-1118322-A1 | DRUGS FOR IMPROVING VESICAL EXCRETORY STRENGTH | Takeda Chemical Industries, Ltd. (JP) | 2001-07-25 | — | — | EP | disclosed |
| WO-2000061559-A1 | N-SUBSTITUTED CYANOGUANIDINE COMPOUNDS | SHIONOGI BIORESEARCH CORP. (US) | 2000-10-19 | — | — | WO | disclosed |
| EP-0975624-A1 | THERMOGENIC COMPOSITION AND BENZAZEPINE THERMOGENICS | Takeda Chemical Industries, Ltd. (JP) | 2000-02-02 | — | — | EP | disclosed |
| WO-1998046590-A1 | THERMOGENIC COMPOSITION AND BENZAZEPINE THERMOGENICS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-10-22 | — | — | WO | disclosed |
| US-5620973-A | CHOLINESTERASE INHIBITOR; ALZHEIMER*S DISEASE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-04-15 | — | — | US | disclosed |
| EP-0655451-A1 | Tetracyclic condensed heterocyclic compounds for the treatment of senile dementia | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1995-05-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021391-A1 | Preventive/remedy for urinary disturbance | ACHE, BCHE, CHAT | RAD52 3088/4885SMARCA2 3327/4885CDK4 4176/4885 |
| US-20090264467-A1 | Agents and crystals for improving excretory potency of urinary bladder | ACHE, BCHE, PDE7A | RAD52 4491/4885SMARCA2 3596/4885CDK4 2518/4885 |
| US-20020177593-A1 | Agents and crystals for improving excretory potency of urinary bladder | ACHE, BPHL, BCHE | RAD52 4647/4885SMARCA2 3783/4885CDK4 2313/4885 |
| US-20070232538-A1 | Uses of polypeptides | NPSR1, SCTR, GRPR | RAD52 2753/4885SMARCA2 2714/4885CDK4 3078/4885 |
| US-20060281725-A1 | Agents and crystals for improving excretory potency of urinary bladder | ACHE, BCHE, PDE7A | RAD52 4537/4885SMARCA2 3551/4885CDK4 2234/4885 |
| US-20060211675-A1 | Preventives/remedies for urinary disturbance | ACHE, BPHL, ACE | RAD52 1582/4885SMARCA2 2932/4885CDK4 4330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.